Beta Drugs Limited Sets a New Industry Benchmark with a Dedicated Oral Suspension Plant for Cancer Medicines

Beta Drugs Limited Sets a New Industry Benchmark with a Dedicated Oral Suspension Plant for Cancer Medicines

Beta Drugs Limited Sets a New Industry Benchmark with a Dedicated Oral Suspension Plant for Cancer Medicines Beta Drugs Limited, a prominent manufacturer of oncology medicines in India, proudly announces the establishment of its cutting-edge oral suspension plant for cancer medicines. This new facility marks a significant milestone in the company’s commitment to advancing cancer treatment options and elevating industry standards.

The oral suspension plant is specifically designed for the production of suspensions and dry syrups of existing cytotoxic drugs. This month, Beta Drugs Limited is set to introduce the NDDS (Novel Drug Delivery System) formulation of Megestrol Acetate suspension, a pioneering product in Asia. This innovative launch underscores the company’s dedication to introducing novel treatment options to benefit cancer patients.

With a focus on delivering high-quality cancer care, Beta Drugs Limited aims to make substantial contributions to improving patient outcomes. Oral suspension and dry syrup formulations of existing cancer medicines are particularly valuable for enhancing patient compliance, especially among pediatric and geriatric cancer patients.

Beta Drugs Limited stands out among Indian oncology companies for its foresight in research and development (R&D) and significant investments in these activities. The company’s R&D team is tirelessly working to develop NDDS formulations and enhance existing oncology treatments through formulation re-innovation. By 2024, Beta Drugs Limited aims to launch over 15 NDDS formulations, including Liposomes, Nanoparticles, Microparticulate systems, suspensions, and dry syrups.

This strategic expansion aligns with Beta Drugs Limited’s vision to establish a strong foothold in the Indian market, as well as in regions outside India and semi-regulated markets. The new facility boasts world-class infrastructure that complies with the highest global regulatory standards and is equipped with state-of-the-art technology.

As Beta Drugs Limited continues to push boundaries and set new standards in cancer treatment, this development is poised to reshape the landscape of cancer care, offering hope and improved healthcare to patients worldwide. With its relentless commitment to innovation and excellence, Beta Drugs Limited is redefining the future of oncology medicine manufacturing.